menu
    • menu
    [{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Junshi Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Adagene Suzhou Limited \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Adagene Suzhou Limited \/ National Institutes of Health"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Xuanzhu Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"KM257","moa":"HER2D4","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sihuan Pharmaceutical \/ Xuanzhu Biopharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Sihuan Pharmaceutical \/ Xuanzhu Biopharmaceutical"},{"orgOrder":0,"company":"Hubei Soundny Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hubei Soundny Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hubei Soundny Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hubei Soundny Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Wigen Biomedicine Technology","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"WJ1075","moa":"XPO1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Wigen Biomedicine Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Wigen Biomedicine Technology \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Wigen Biomedicine Technology \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"FCN-338","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Fosun Pharmaceutical \/ Eli Lilly"},{"orgOrder":0,"company":"Antengene","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ WuXi Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Antengene \/ WuXi Biologics"},{"orgOrder":0,"company":"Chengdu Baiyu Pharmaceutical","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Chengdu Baiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chengdu Baiyu Pharmaceutical \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Chengdu Baiyu Pharmaceutical \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Hillhouse Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"I-Mab Biopharma \/ Hillhouse Capital Group","highestDevelopmentStatusID":"1","companyTruncated":"I-Mab Biopharma \/ Hillhouse Capital Group"},{"orgOrder":0,"company":"Asymchem Laboratories","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Asymchem Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asymchem Laboratories \/ LaNova Medicines","highestDevelopmentStatusID":"1","companyTruncated":"Asymchem Laboratories \/ LaNova Medicines"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GC027","moa":"T-cell receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"}]

    Find Novel Oncology Drugs in Clinical Development in CHINA

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chengdu Baiyu Pharmaceutical

                            China arrow
                            EPS
                            Not Confirmed

                            Chengdu Baiyu Pharmaceutical

                            China arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,170.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Novartis Pays Baiyu $70M, with $1.1B Chaser, for Cancer Prospect

                            Details : The deal covers the global rights to a small molecule discovered by a Chinese biotech that has built a business around botanical drugs.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $70.0 million

                            October 16, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,170.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ascentage Pharma

                            China arrow
                            EPS
                            Not Confirmed

                            Ascentage Pharma

                            China arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olverembatinib

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $1,300.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ascentage Pharma Received US$100 Million Option Payment from Takeda

                            Details : Ascentage and Takeda entered into an agreement that granted Takeda an exclusive option to enter into an exclusive license agreement for HQP1351 (olverembatinib) for Chronic Myeloid Leukemia.

                            Product Name : HQP1351

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 07, 2024

                            Lead Product(s) : Olverembatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $1,300.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ablaze Pharma

                            China arrow
                            EPS
                            Not Confirmed

                            Ablaze Pharma

                            China arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225-Ac

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Yonghe Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targete...

                            Details : Actinium-225 is an alpha emitting radioactive particle that has high energy density acting at distances of just a few cell widths. At these short distances, radiation can be restricted to the cancer cells of interest with minimal risk to nearby normal he...

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            December 27, 2022

                            Lead Product(s) : 225-Ac

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Yonghe Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sichuan Kelun Pharmaceutical

                            China arrow
                            EPS
                            Not Confirmed

                            Sichuan Kelun Pharmaceutical

                            China arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Merck & Co

                            Deal Size : $1,407.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            China’s Kelun Pharma Jumps on Licensing New Cancer Drug to Holland’s Merck Sharp & Dohme

                            Details : The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing of upfront cash in exchange for ex-China rights to a “macromolecular tumor project".

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : $47.0 million

                            May 16, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Merck & Co

                            Deal Size : $1,407.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Full-Life Technologies

                            China arrow
                            EPS
                            Not Confirmed

                            Full-Life Technologies

                            China arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Focus-X Therapeutics

                            Deal Size : $245.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Ful...

                            Details : Focus-X is developing targeted radiopharmaceuticals-based therapeutic to treat cancer based on its proprietary peptide engineering technology. Viva also provided Focus-X with comprehensive incubation services to help it realize the transformation from co...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 12, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Focus-X Therapeutics

                            Deal Size : $245.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Adagene Suzhou Limited

                            China arrow
                            EPS
                            Not Confirmed

                            Adagene Suzhou Limited

                            China arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the N...

                            Details : As a result of the collaboration, Adagene discovered antibodies that Dr. Child’s laboratory has turned into a CAR-T cell therapy candidate for the potential treatment of renal cell carcinoma, the most common type of kidney cancer in adults, according t...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 01, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Asymchem Laboratories

                            China arrow
                            EPS
                            Not Confirmed

                            Asymchem Laboratories

                            China arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : LaNova Medicines

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Asymchem and LaNova Medicines Enter into Partnership Agreement, Expanding Biological Capabilities

                            Details : The partnership between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 16, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : LaNova Medicines

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sihuan Pharmaceutical

                            China arrow
                            EPS
                            Not Confirmed

                            Sihuan Pharmaceutical

                            China arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KM257

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Xuanzhu Biopharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Xuanzhu Biopharm Acquires Combio Pharmaceutical

                            Details : Combio Pharmaceutical product pipeline already has 12 products under development, of which KM257/252 is a bispecific antibody drug for cholangiocarcinoma, breast cancer, gastroesophageal cancer, etc.

                            Product Name : KM257

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 27, 2021

                            Lead Product(s) : KM257

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Xuanzhu Biopharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            MediLink Therapeutics

                            China arrow
                            EPS
                            Not Confirmed

                            MediLink Therapeutics

                            China arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Apricot Capital

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs ...

                            Details : The series A financing will help in accelerating Medilink's innovative pipeline development and to support its unique conjugate technology platform.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 03, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Apricot Capital

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Fosun Pharmaceutical

                            China arrow
                            EPS
                            Not Confirmed

                            Fosun Pharmaceutical

                            China arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FCN-338

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Eli Lilly

                            Deal Size : $440.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Fochon Pharmaceuticals Announces Licensing Agreement with Eli Lilly and Company for Novel Selective BCL-2 Inhi...

                            Details : Lilly gains exclusive rights to develop and sell FCN-338 in all countries and regions except for Mainland China, Macao, and Hong Kong. Fochon reserves all right to research, develop, register, manufacture, and market FCN-338 in Mainland China, Macao, and...

                            Product Name : FCN-338

                            Product Type : Other Small Molecule

                            Upfront Cash : $40.0 million

                            October 30, 2020

                            Lead Product(s) : FCN-338

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Eli Lilly

                            Deal Size : $440.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth